{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:27:18Z","timestamp":1787218038818,"version":"build-2736575974"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Baveno VII consensus formally defined cirrhosis recompensation in 2022, marking an important milestone in the transition of cirrhosis management from complication control toward disease modification. This concept did not emerge abruptly but was built on decades of research concerning etiological control, fibrosis regression, portal hypertension control, liver function recovery, and reversal of decompensation. However, the evolution of these knowledge domains, the key milestones shaping the field, and the clinical or mechanistic directions that should be prioritized remain unclear. This study used bibliometric analysis to map the development and trends of cirrhosis recompensation-related research, with emphasis on recent advances and future directions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Relevant publications (up to May 31, 2026) were retrieved from the Web of Science Core Collection (WoSCC) and PubMed. Bibliometric visualization and network analyses were performed using CiteSpace, VOSviewer, bibliometrix, R, and Python to examine publication trends, global collaborations, core journals, author networks, co-cited references, keyword evolution, citation bursts, and randomized controlled trial (RCT) evidence mapping.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 588 WoSCC publications and 168 PubMed RCT publications were included. The field showed a three-stage evolution: complication control and survival prolongation; etiology-directed therapy and fibrosis regression; and recompensation-centered disease modification after Baveno VII. The United States and China were leading contributors, while Journal of Hepatology and Hepatology were central journals. Co-citation and keyword analyses highlighted antiviral therapy, fibrosis regression, portal hypertension, and recompensation as major knowledge themes. Further within-WoSCC mapping of the 31-publication RCT subset showed that no publication evaluated formal Baveno VII recompensation as an explicit endpoint. Complementary analysis of the 168 PubMed RCT publications showed that recompensation was not evaluated as an endpoint even among publications reporting follow-up beyond 48 weeks, indicating that this gap could not be attributed solely to short follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This bibliometric analysis delineates the evolving landscape of cirrhosis recompensation-related research, characterized by a transition from complication control to disease modification and an increasing focus on recompensation after Baveno VII. Persistent gaps in RCT evidence, especially regarding recompensation endpoints and long-term disease-modification outcomes, underscore the need for continued high-quality clinical and translational studies in this field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1921542","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:10:33Z","timestamp":1787217033000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From fibrosis regression to recompensation: bibliometric and clinical evidence mapping of disease modification in cirrhosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Han-Wen","family":"Zhang","sequence":"first","affiliation":[{"name":"Medical School of Chinese PLA","place":["Beijing, China"]},{"name":"Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ling","family":"Wu","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA","place":["Beijing, China"]},{"name":"Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA","place":["Beijing, China"]},{"name":"Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Zhuang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Hainan Hospital of Chinese PLA General Hospital","place":["Sanya, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Huang","family":"Peng","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA","place":["Beijing, China"]},{"name":"Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Xuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA","place":["Beijing, China"]},{"name":"Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Ya","family":"Huang","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA","place":["Beijing, China"]},{"name":"Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Luan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-Tao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hainan Hospital of Chinese PLA General Hospital","place":["Sanya, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world.","volume":"70","author":"Asrani","year":"2019","journal-title":"J Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"5","author":"Sepanlou","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis.","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis.","volume":"69","author":"Angeli","year":"2018","journal-title":"J Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis.","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis.","volume":"383","author":"Tsochatzis","year":"2014","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B.","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA."},{"key":"B10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis.","volume":"56","author":"D\u2019Ambrosio","year":"2012","journal-title":"Hepatology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension.","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature.","volume":"57","author":"Chen","year":"2006","journal-title":"J Am Soc Information Sci Technol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping.","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics."},{"key":"B14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","article-title":"bibliometrix : an R-tool for comprehensive science mapping analysis.","volume":"11","author":"Aria","year":"2017","journal-title":"J Informetrics."},{"key":"B15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jbusres.2021.04.070","article-title":"How to conduct a bibliometric analysis: an overview and guidelines.","volume":"133","author":"Donthu","year":"2021","journal-title":"J Bus Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jhep.2022.07.037","article-title":"Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis.","volume":"77","author":"Wang","year":"2022","journal-title":"J Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/liv.15676","article-title":"Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis.","volume":"43","author":"Hofer","year":"2023","journal-title":"Liver Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.","volume":"37","author":"Bachofner","year":"2016","journal-title":"Liver Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.dld.2022.12.014","article-title":"The baveno VII concept of cirrhosis recompensation.","volume":"55","author":"Reiberger","year":"2023","journal-title":"Dig Liver Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/jvh.12578","article-title":"Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy.","volume":"23","author":"Knop","year":"2016","journal-title":"J Viral Hepat."},{"key":"B21","doi-asserted-by":"publisher","first-page":"100814","DOI":"10.1016\/j.jhepr.2023.100814","article-title":"Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis.","volume":"5","author":"Hui","year":"2023","journal-title":"JHEP Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1053\/j.gastro.2012.02.017","article-title":"Noninvasive methods to assess liver disease in patients with hepatitis B or C.","volume":"142","author":"Castera","year":"2012","journal-title":"Gastroenterology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"101233","DOI":"10.1016\/j.jhepr.2024.101233","article-title":"Mechanisms and implications of recompensation in cirrhosis.","volume":"6","author":"Piano","year":"2024","journal-title":"JHEP Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1053\/j.gastro.2024.08.018","article-title":"Recompensation of chronic hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: prospective cohort study from a hepatitis C virus elimination program.","volume":"167","author":"Premkumar","year":"2024","journal-title":"Gastroenterology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12876-026-04651-6","article-title":"Recompensation following first decompensation in patients with alcohol-related cirrhosis.","volume":"26","author":"Kwak","year":"2026","journal-title":"BMC Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1765594","DOI":"10.3389\/fmed.2026.1765594","article-title":"Ishak stage 6 fibrosis is more likely to regress than stage 5 in CHB patients undergoing entecavir therapy.","volume":"13","author":"Li","year":"2026","journal-title":"Front Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.4254\/wjh.v16.i7.1009","article-title":"Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years.","volume":"16","author":"Huynh","year":"2024","journal-title":"World J Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.","volume":"75","year":"2021","journal-title":"J Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease.","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American association for the study of liver diseases.","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","article-title":"Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites.","volume":"152","author":"Bureau","year":"2017","journal-title":"Gastroenterology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.","volume":"3","author":"Razavi-Shearer","year":"2018","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B35","volume-title":"Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries.","year":"2024"},{"key":"B36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis.","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Invest."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis.","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression.","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: concept to treatment.","volume":"62","author":"Trautwein","year":"2015","journal-title":"J Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet."},{"key":"B41","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome.","volume":"384","author":"Wong","year":"2021","journal-title":"N Engl J Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy.","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/JCI30542","article-title":"Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ.","volume":"117","author":"Iredale","year":"2007","journal-title":"J Clin Invest."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1921542\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:10:34Z","timestamp":1787217034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1921542\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":45,"alternative-id":["10.3389\/fmed.2026.1921542"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1921542","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1921542"}}